EUVIMEDEUVIMED entdecken
Open Access

Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors

Anoopjit Singh Kooner iD, Mariah Norman, Igi Vilza iD, Michael P Mannino iD, Mary Savari Dhason, Jon Helander, Shrushti Patil iD, L David Sibley, James W Janetka iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202500440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Anoopjit Singh Kooner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, 63110, USA. Hauptthemen laut MEDLINE: Toxoplasma, Protein Kinase Inhibitors, Drug Design, Protein Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toxoplasmosis is caused by the protozoan parasite Toxoplasma gondii and poses grave health concern for immunocompromised patients. T. gondii has a family of calcium dependent protein kinases (CDPKs) that control a variety of critical processes. Among these, Tg CDPK1 is required for parasite motility, cell invasion, and egress and hence is essential both for in vitro growth of T. gondii and to cause infections in animals. Using existing X‐ray cocrystal structures of pyrazolopyrimidine (PP) inhibitors bound to Tg CDPK1, six new chemical series of inhibitors are rationally designed. The synthesis of analogs based on the most promising novel series is pursued, which resulted in potent Tg CDPK1 inhibitors that effectively block parasite growth in cells. The resulting lead compounds 44 and 45 belonging to the imidazopyrazine chemical series demonstrate the promising potential of this new class of inhibitors for the treatment and possible cure of the Toxoplasmosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ToxoplasmaProtein Kinase InhibitorsDrug DesignProtein KinasesHeterocyclic CompoundsProtozoan ProteinsStructure-Activity RelationshipCrystallography, X-RayHumansMolecular StructurePyrazolesPyrimidinesModels, MolecularAnimalsCalcium-Calmodulin-Dependent Protein Kinases

Stichwörter der Autor:innen

calcium dependent protein kinase 1kinase inhibitorstructure‐based drug designtoxoplasmosis

Substanzen

Protein Kinase InhibitorsProtein KinasesHeterocyclic CompoundsProtozoan ProteinsPyrazolesPyrimidinesCalcium-Calmodulin-Dependent Protein Kinases

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, 63110, USA.
  • Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.

ORCID-Profile: Anoopjit Singh Kooner, Igi Vilza, Michael P Mannino, Shrushti Patil, James W Janetka

Förderung

  • NIAID NIH HHS
  • NIH HHS

Zitieren

APA

Kooner, A. S., Norman, M., Vilza, I., Mannino, M. P., Dhason, M. S., Helander, J., Patil, S., Sibley, L. D., & Janetka, J. W. (2025). Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors. ChemMedChem. https://doi.org/10.1002/cmdc.202500440

Vancouver

Kooner AS, Norman M, Vilza I, Mannino MP, Dhason MS, Helander J, et al. Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors. ChemMedChem. 2025. doi:10.1002/cmdc.202500440

BibTeX
@article{Kooner2025,
  author = {Kooner, Anoopjit Singh and Norman, Mariah and Vilza, Igi and Mannino, Michael P and Dhason, Mary Savari and Helander, Jon and Patil, Shrushti and Sibley, L David and Janetka, James W},
  title = {Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202500440}
}
Kostenlos starten →